ArticleBMJ open2026
Cost-effectiveness of patellofemoral arthroplasty compared with total knee arthroplasty: a cohort study using data from the National Joint Registry for England.
Article in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTotal knee replacement (TKR) and patellofemoral joint replacement (PFR) are both surgical options for patellofemoral joint osteoarthritis. This study aimed to determine which procedure is more cost-effective.
methodsA Markov model was constructed to evaluate the cost-effectiveness of PFR compared with TKR, using revision risk and age-specific mortality derived from UK life tables. A model-based economic evaluation was conducted from an NHS healthcare perspective, with costs derived from NHS reference costs. The model used a 60-year time horizon with annual cycles. Utility values were derived from patient-reported outcome measures collected between 6 and 18 months postoperatively and linked to 900 PFR and 287 777 TKR cases from the National Joint Registry.To ensure comparability between groups, inverse probability of treatment weighting was used to adjust for age, sex, American Society of Anaesthesiologists classification, social deprivation indices, anaesthesia type, healthcare provider, surgeon experience, Charlson Comorbidity Index and preoperative EQ-5D-3L and Oxford Knee Scores.
resultsPFR was associated with lower costs than TKR, with an initial per-patient saving of approximately £4000. In younger patients, PFR was associated with slightly lower quality-adjusted life years (QALYs) compared with TKR, whereas in older patients it was associated with marginally higher QALYs. These differences resulted in variation in incremental cost-effectiveness ratios (ICERs) across age groups, with a trend towards greater cost-effectiveness of PFR in older populations. Cost savings decreased with age due to lower revision rates in older populations. Similar trends were observed across both sexes, although males experienced greater QALY gains, while PFR was more cost-effective overall in females. In younger patients, TKR was linked to higher costs and marginally lower effectiveness, though the difference in cost-effectiveness between PFR and TKR in this group was minimal.One-way sensitivity analysis demonstrated that the model was highly sensitive to assumptions regarding postoperative utility following both PFR and TKR, with variation sufficient to alter the direction of the ICER. In contrast, revision utility and discount rate had relatively minor effects.
conclusionPFR may be a cost-effective alternative to TKR under certain assumptions, particularly in older patients; however, substantial decision uncertainty remains, driven primarily by variation in postoperative utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.